NCT06991712View on ClinicalTrials.gov

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Glaucoma
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks

DIETARY_SUPPLEMENT

Nicotinamide

Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks

DIETARY_SUPPLEMENT

Nicotinamide Mononucleotide

Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks

DIETARY_SUPPLEMENT

Nicotinic Acid

Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks

OTHER

Placebo (Corn Starch)

Oral supplementation of 300mg Placebo daily for 2 weeks

OTHER

Placebo (Corn Starch)

Oral supplementation of 300mg Placebo daily for 2 weeks

Trial Locations (1)

Unknown

RECRUITING

HKU Eye Centre, Wong Chuk Hang

All Listed Sponsors
lead

Christopher Kai Shun Leung

OTHER